| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Addex Therapeutics Ltd$6
-0.45 (-6.98%)
D 33Pipeline Score Overvalued Pharma · Clinical
Market Cap
6.89 M
EPS
-9.10
P/E Ratio
-0.7 $
Value Trade
6.33 K
0.29 %
Week
-2.43 %
1 Month
-7.07 %
3 Month
-13.54 %
6 Month
-96.52 %
5 Year
-97.64 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
5.62 K
52 Week Range
5.41 - 12.05
% held by Insiders
0.03 %
% held by Institutions
0.05 %
Enterprise Value
4.86 M
Total Shares
982.73 K
Short %
0.51 %
Float Shares
982.44 K
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D33
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.4x
rNPV / MCap Top 44%
Micro Cap (rank 508 of 905)
Percentile RankAddex Therapeutics Ltd faces pipeline headwinds (33/100), with $983M risk-adjusted pipeline value, led by ADX10059 in Gastroesophageal Reflux (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADX10059 Small molecule | Gastroesophageal Reflux | Phase 2 | NCT00820079 | 16% | $679M | COMPLETED | 418 | - | - | — | - | Dec 24, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 | |||
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 | |||
dipraglurant | brain injury recovery,chronic cough,substance use disorders | Phase 2 | 2025-06-19 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADXN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ADXN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ADXN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADXNAddex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Addex Therapeutics will report its First Quarter 2026 Financial Results on June 25, 2026. During a teleconference, CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will discuss the company's product pipeline and provide a business update. The event will be accessible to investors, analysts, and media.
Read more →ADXNAddex Convenes Annual General Meeting 2026
Addex Therapeutics has announced its 2026 Annual General Meeting (AGM) scheduled for June 29, 2026, in Geneva. At the meeting, shareholders will review and approve the annual report and financial statements for 2025, alongside various re-elections of board members and discussions on compensation. The company also plans to address amendments to its Articles of Association during the AGM, signaling ongoing corporate governance and strategic planning.
Read more →ADXNAddex Reports Full Year 2025 Financial Results and Provides Corporate Update
Addex Therapeutics reported its full-year 2025 financial results, highlighting progress in its GABAB PAM chronic cough candidate and the advancement of dipraglurant for brain injury recovery. The company regained rights to its mGlu2 PAM asset, ADX71149, and entered a collaboration with Sinntaxis. Despite a decrease in income and an overall net loss, Addex remains committed to developing innovative treatments for neurological disorders.
Read more →ADXNAddex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Addex Therapeutics announced promising preclinical results for its GABAB PAM candidate, showing significant antitussive activity in a bleomycin-induced chronic cough model. The compound demonstrated reduced cough frequency and improved lung pathology without adverse effects. This positions the candidate as a potential treatment for chronic cough in idiopathic pulmonary fibrosis patients.
Read more →ADXNAddex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Addex Therapeutics announced that its spin-out company, Neurosterix, is on track to complete a Phase 1 clinical study of NTX-253 for schizophrenia by Q2 2026. The study aims to evaluate the safety, tolerability, and pharmacokinetics of NTX-253, a positive allosteric modulator of the muscarinic M4 receptor. It includes both healthy participants and those with stable schizophrenia, with a focus on generating robust early-stage clinical data.
Read more →ADXNAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Addex Therapeutics announced promising results for its GABAB PAM candidate, showing significant anti-tussive activity in a non-human primate model of chronic cough. The drug candidate reduced cough frequency similarly to baclofen but with fewer side effects. This positions the GABAB PAM as a potential once-daily treatment option for chronic cough patients.
Read more →ADXNAddex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Addex Therapeutics announced the publication of preclinical data in Molecular Psychiatry, highlighting the potential of mGlu7 negative allosteric modulators (NAMs) to transform treatments for anxiety and fear-related disorders. The study showed that ADX71743 can disrupt fear memory reconsolidation, suggesting a novel therapeutic approach. This research may lead to more effective treatments for conditions like PTSD.
Read more →ADXNAddex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Addex Therapeutics announced that its spin-out company Neurosterix has commenced a Phase 1 clinical study for NTX-253, a selective positive allosteric modulator of the M4 receptor intended for schizophrenia treatment. This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy participants. This milestone is significant for both Neurosterix and Addex, as it showcases a novel therapeutic strategy to reduce psychosis symptoms while potentially minimizing traditional antipsychotic side effects.
Read more →ADXNAddex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co. This amendment allows Addex to offer and sell American Depositary Shares (ADSs) for up to $3.3 million at its discretion. The company is not obligated to sell any ADSs, and the agreement includes customary sales commissions and indemnification rights.
Read more →ADXNADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of
ADDEX Therapeutics Ltd has released its unaudited interim condensed consolidated financial statements for the nine-month period ending September 30, 2025. The company reported a net loss of 4,891,259 Swiss francs during this period, indicating deterioration compared to prior years. Furthermore, total assets declined significantly by over 3 million Swiss francs, underscoring financial challenges. Operating costs also rose, contributing to a notable operating loss of 2,035,335 Swiss francs.
Read more →ADXNAddex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Addex Therapeutics reported its Q3 2025 financial results, highlighting significant advancements in its drug candidates, particularly in chronic cough and post-stroke recovery. While the company has made progress in research and development, it also recorded a decline in income and an increase in net losses compared to the previous year. Additionally, the firm observed a decrease in cash reserves over the same period, raising potential concerns about future liquidity. A conference call is scheduled for further discussions on these results.
Read more →ADXNAddex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
Addex Therapeutics will report its Q3 2025 financial results on December 4, 2025. CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will provide a business update and discuss the company's product pipeline during a teleconference and webcast. The event aims to inform investors, analysts, and media about the company's progress and future plans.
Read more →ADXNAddex Increases Issued Share Capital to Create Treasury Shares
Addex Therapeutics has announced the issuance of 34.3 million new shares through its wholly-owned subsidiary, Addex Pharma S.A. This increase in share capital aims to provide the company with greater financing flexibility for future developments. The total issued share capital now stands at CHF 2,186,544.96, while the number of outstanding shares remains unchanged.
Read more →ADXNAddex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Addex Therapeutics reported its half-year and second quarter financial results for 2025, highlighting significant progress in drug development, particularly with its GABAB PAM candidate for chronic cough. The company regained rights to its Phase 2 mGlu2 PAM asset, ADX71149, and presented positive data at the American Cough conference. However, financial results showed a decrease in income and cash reserves compared to the previous year.
Read more →ADXNAddex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
Addex Therapeutics will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025, and host a conference call on October 1, 2025. During the call, CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will review the company's product pipeline. Addex is focused on developing small molecule allosteric modulators for neurological disorders, and has a variety of candidates in its portfolio, including treatment for brain injury recovery. Participants must register in advance to join the conference call.
Read more →ADXNAddex Appoints Bank of New York Mellon as Depositary Bank
Addex Therapeutics has appointed the Bank of New York Mellon as its new ADS depositary agent, effective October 6, 2025. This change will not affect the fees paid by ADS holders, who will not need to take any action. The appointment underscores Addex's commitment to maintaining strong financial partnerships as it advances its clinical-stage drug development.
Read more →ADXNAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Addex Therapeutics announced a CHF 2 million investment in Stalicla, a company focused on precision medicine for neurodevelopmental disorders. The funds will be used to advance Stalicla's autism drug candidates and to support its Series C financing. Addex's CEO, Tim Dyer, joins Stalicla's Board of Directors, underscoring the strategic partnership. Stalicla is poised to initiate Phase 2 trials for its leading candidates, targeting specific subpopulations within the autism spectrum disorder. This investment reflects Addex's dedication to developing treatments for central nervous system disorders.
Read more →ADXNAddex Shareholders Approve All Resolutions at Annual General Meeting
Addex Therapeutics announced that shareholders approved all board proposals during its 2025 Annual General Meeting. Key approvals included the annual report and compensation for directors. Dr. Vincent Lawton and other board members were re-elected, ensuring continuity in leadership. The company continues to focus on developing allosteric modulators for neurological disorders.
Read more →ADXNAddex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Addex Therapeutics has reported its Q1 2025 financial results, highlighting a strong cash position of CHF2.8 million. The company has demonstrated promising anti-tussive activity for its GABAB PAM chronic cough candidate and has regained rights to its mGlu2 PAM asset, ADX71149. Notably, Indivior has advanced its GABAB PAM program for substance use disorders through IND enabling studies. However, the company experienced a decrease in income and an increase in net loss from continuing operations compared to the previous year.
Read more →ADXNAddex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
Addex Therapeutics will announce its Q1 2025 financial results on June 19, 2025. The CEO and Head of Translational Science will discuss the company's product pipeline during a teleconference and webcast. The company focuses on developing allosteric modulators for neurological disorders, with several promising drug candidates in development.
Read more →ADXNAddex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Addex Therapeutics announced that its GABAB PAM candidate exhibited significant anti-tussive effects in various preclinical models of chronic cough, outperforming traditional treatments. The candidate demonstrated improved tolerability and a wider therapeutic margin. The data will be presented at the upcoming American Cough Conference, and the company plans to advance the candidate into IND enabling studies.
Read more →ADXNAddex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
Addex Therapeutics will present preclinical data on its GABAB PAM cough program at the 10th American Cough Conference. The presentation will highlight the antitussive efficacy of Compound A and its readiness for IND enabling studies. The company aims to leverage the advantages of allosteric modulation to improve treatment for chronic cough.
Read more →ADXNAddex Convenes Annual General Meeting 2025
Addex Therapeutics has announced that its 2025 Annual General Meeting will occur on June 24, 2025, in Geneva. Key agenda items include the approval of the Annual Report and Financial Statements for 2024, discussions on compensation, and re-elections of board members. The meeting reflects the company's ongoing commitment to transparency and governance as it continues to develop novel treatments for neurological disorders. Additionally, Addex’s lead drug candidate, dipraglurant, is under evaluation for brain injury recovery applications.
Read more →ADXNAddex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Addex Therapeutics has announced that its partner, Indivior, has successfully completed IND enabling studies for their GABAB positive allosteric modulator (PAM) program, a crucial step before clinical trials. Tim Dyer, CEO of Addex, highlighted the significant achievements stemming from their research collaboration. Under their agreement, Addex stands to gain up to USD 330 million in payments and royalties related to the successful development of these compounds. Furthermore, Addex is advancing its own GABAB PAM program for chronic cough, indicating ongoing progress in its portfolio of neurological disorder treatments.
Read more →ADXNAddex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Addex Therapeutics has signed a collaboration agreement with Sinntaxis for an exclusive license concerning the use of mGlu5 inhibitors in brain injury recovery. This includes a research plan for evaluating Addex's dipraglurant, a negative allosteric modulator, aimed at treating recovery in patients following brain injuries such as strokes. The agreement underscores the company’s strategy to reposition dipraglurant as a clinical candidate for a significant medical need. Both companies aim to complete preclinical validations and enhance recovery methods for brain injury patients.
Read more →ADXNAddex Reports Full Year 2024 Financial Results and Provides Corporate Update
Addex Therapeutics reported its financial results for the full year 2024, highlighting significant advancements in its clinical programs. The company launched Neurosterix, raising USD 65 million to develop its preclinical portfolio and partnered with Indivior to further develop drug candidates for substance use disorders. Despite these positive strides, Addex experienced an increased net loss from continuing operations, reflecting challenges in revenue generation. Overall, the company is positioned for future growth with the regained rights to key assets and ongoing progress in clinical development.
Read more →ADXNAddex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
Addex Therapeutics has announced the upcoming release of its Full-Year 2024 Financial Results, scheduled for April 25, 2025. During this event, CEO Tim Dyer and Mikhail Kalinichev will discuss the business updates and the company's product pipeline. The teleconference and webcast will be available for investors, analysts, and media. This announcement highlights the company's ongoing development of novel small molecule allosteric modulators for neurological disorders.
Read more →ADXNAddex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
Addex Therapeutics announced the termination of its partnership with Janssen Pharmaceuticals, regaining full rights to ADX71149. This asset has completed three Phase 2 studies and offers a solid data package for future therapeutic development. The company plans to explore various high-value indications and engage potential partners for further progress in the program. This strategic move may benefit Addex in capitalizing on its asset independently.
Read more →ADXNAddex to Present at the 2025 Swiss Equities Baader Conference
Addex Therapeutics announced that Dr. Robert Lütjens will present at the Swiss Equities Baader Conference in Bad Ragaz, Switzerland, on January 10, 2025. The presentation will include a corporate update and recent advancements in Addex's CNS pipeline. The company is known for developing allosteric modulators aimed at treating neurological disorders, further enhancing its presence in the biopharmaceutical sector.
Read more →ADXNAddex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Addex Therapeutics announced its third quarter financial results for 2024, reporting a net loss of CHF 1.5 million. The company highlighted a successful collaboration with Indivior, which selected a GABAB PAM drug candidate for substance use disorders. Addex also mentioned the selection of its own proprietary GABAB PAM candidate to potentially treat chronic cough. Overall, despite collaboration successes, the company faces challenges with decreasing income and a net loss from continuing operations.
Read more →ADXNAddex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Addex Therapeutics reported a significant decrease in net results for the third quarter of 2024, with a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million in the second quarter. The downturn is attributed to a non-recurring gain from a business sale earlier in the year. Despite this, the company still recorded a net profit of CHF 8.3 million for the nine-month period ending September 30, 2024. Addex anticipates further losses in the upcoming quarters as it continues to develop its pipeline of neurological disorder therapies.
Read more →ADXNAddex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Addex Therapeutics reported its 2024 half-year and second quarter financial results, highlighting major milestones such as the launch of Neurosterix and the selection of drug candidates for further development. The company secured $63 million in Series A funding to advance its drug portfolio, while also experiencing increased operating losses. Net profit from discontinued operations saw a substantial increase, primarily due to the sale of part of its business. However, the overall decline in income and cash reserves remains a concern for future operations.
Read more →ADXNAddex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Addex Therapeutics reported a provisional net profit of CHF 9.8 million for the first half of 2024, a remarkable turnaround from a net loss of CHF 5.1 million in the same period of 2023. This positive shift is primarily attributed to the sale of part of its business to Neurosterix Pharma. The company plans to release its final Half-Year 2024 Financial Results on September 30, 2024. Addex is also actively advancing several clinical programs in the neurological disorder sector.
Read more →ADXNAddex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Addex Therapeutics announced that CEO Tim Dyer will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Dyer's pre-recorded video presentation will provide a corporate update and discuss recent developments in the company's drug candidates for neurological disorders. Additionally, one-on-one meetings will be available for attendees. While there are optimistic developments, the company also acknowledges market uncertainties that could impact future outcomes.
Read more →ADXNAddex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Addex Therapeutics and Indivior PLC have announced the selection of clinical candidates from their collaboration on GABAB positive allosteric modulators. Indivior will develop a compound aimed at treating substance use disorders, while Addex will advance a candidate for chronic cough treatment. The agreement allows Addex potential earnings of up to USD 330 million, highlighting the financial benefits of their partnership. The GABAB PAM approach may offer innovative therapies with fewer side effects compared to existing options.
Read more →ADXNAddex’s Partner Discontinues ADX71149 development in Epilepsy
Addex Therapeutics announced that its partner Janssen Pharmaceuticals has discontinued the development of ADX71149 for epilepsy. This decision follows disappointing results from a Phase 2 study which showed that the drug did not meet the primary endpoint for reducing seizure counts. Despite this setback, Addex continues to collaborate with Janssen to analyze the complete data set from the study before making any future decisions regarding the asset. The companies will maintain their ongoing partnership while this analysis takes place.
Read more →ADXNAddex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Addex Therapeutics announced positive results for its GABAB PAM chronic cough program, set to be presented at the Thirteenth London International Cough Symposium. The novel allosteric modulator significantly reduced cough frequency in guinea pig models without developing tolerance. Furthermore, it displayed a wider safety margin than baclofen, a current treatment for chronic cough, which is limited by side effects. This positions the candidate as a promising option for chronic cough therapy.
Read more →ADXNAddex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Addex Therapeutics will be presenting at the Thirteenth London International Cough Symposium, where Mikhail Kalinichev will discuss the antitussive activity of a novel GABAB receptor positive allosteric modulator. The symposium is scheduled for July 18-19, 2024, at Imperial College London. This presentation emphasizes the company's ongoing efforts to address chronic cough through innovative therapeutic approaches involving GABAB receptor activation.
Read more →ADXNAddex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Addex Therapeutics has reported their Q1 2024 financial results, revealing a significant net loss and decreased income compared to the previous year. Despite these financial challenges, the company anticipates the selection of drug candidates under its collaboration with Indivior by the end of Q2 2024, aiming to advance various therapeutic programs. Additionally, funds raised from the recent Neurosterix transaction are expected to support the development of their preclinical portfolio. The company's ongoing partnerships and drug development efforts are essential to their strategic focus moving forward.
Read more →ADXNAddex Convenes Annual General Meeting 2024
Addex Therapeutics has announced that its 2024 Annual General Meeting is scheduled for June 28, 2024, in Geneva, Switzerland. The agenda includes the approval of the 2023 Annual Report and Financial Statements, the re-election of board members, and amendments to the Articles of Association. Additionally, Addex is progressing its clinical pipeline, including treatments for epilepsy and Parkinson's disease, highlighting its focus on neurological disorders.
Read more →ADXNAddex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Addex Therapeutics has announced it will release its financial results for Q1 2024 on June 6, 2024. The event will be accompanied by a conference call featuring CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev, who will discuss the company’s product pipeline. The announcement highlights the focus on novel allosteric modulators for neurological disorders. This upcoming call aims to keep investors and analysts informed about the company's progress and developments.
Read more →ADXNAddex to Present at Bio€quity Europe 2024
Addex Therapeutics will have its CEO, Tim Dyer, present at the Bioequity Europe 2024 conference, scheduled for May 12 - 14, 2024, in San Sebastián, Spain. Dyer will deliver a corporate update and discuss recent developments in the company, including progress on their drug candidates. Addex recently completed a Phase 2 study for ADX71149, aimed at treating epilepsy, and is advancing various programs for neurological disorders. Attendees can schedule one-on-one meetings with Dyer during the conference for more information on Addex’s developments.
Read more →ADXNAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
Addex Therapeutics has reported top-line data from its Phase 2 study of ADX71149 for epilepsy, which failed to meet its primary endpoint concerning seizure count. The trial included 110 evaluable patients and showed that while the treatment was safe and well tolerated, it did not statistically improve outcomes when added to standard care. Despite this setback, Addex remains focused on progressing its other allosteric modulator programs, including a GABAB PAM collaboration with Indivior.
Read more →ADXNAddex to Present at the Swiss Biotech Day 2024
Addex Therapeutics announced that CEO Tim Dyer will present at the Swiss Biotech Day 2024 from April 22-23, 2024, in Basel, Switzerland. During his presentation, Dyer will provide a corporate update and discuss recent developments in the company, which is focusing on novel allosteric modulators for neurological disorders. The company is involved in multiple clinical programs, including treatments for epilepsy and dyskinesia associated with Parkinson's disease. Additionally, Dyer will be available for one-on-one meetings with attendees of the conference.
Read more →ADXNAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Addex Therapeutics reported its full-year financial results for 2023, showcasing improved financial performance amid ongoing developments. The company successfully launched Neurosterix, raising $63 million to boost its preclinical portfolio. Anticipated top-line data from the Phase 2 epilepsy study of ADX71149 is expected by mid-May 2024, while collaborative efforts with Indivior continue to advance new drug candidates. Despite a decrease in net loss, the company still faces challenges such as a high operating loss and reduced cash reserves.
Read more →ADXNAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Addex Therapeutics announced it will release its Full-Year 2023 Financial Results on April 18, 2024. During a conference call, CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will provide business updates and discuss the company’s product pipeline. The call will be accessible to investors, analysts, and media, showcasing Addex's efforts in allosteric modulation for treating neurological disorders. The company remains active in advancing its clinical programs, particularly in epilepsy and Parkinson’s disease treatment.
Read more →ADXNAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex Therapeutics has partnered with Perceptive Advisors to launch Neurosterix, a new company aimed at developing allosteric modulators for neurological disorders. The venture is backed by an investment of $63 million, which will enable the acquisition of Addex's preclinical assets and technology. In exchange, Addex will receive CHF5 million and a 20% share in Neurosterix. This partnership not only extends Addex's financial runway but also highlights the company's innovative drug discovery platform.
Read more →ADXNAddex to Present at the Bio-Europe Spring 2024 Conference
Addex Therapeutics will be represented at the Bio-Europe Spring 2024 conference in Barcelona, where CEO Tim Dyer will present a corporate update. The presentation is scheduled for March 19, 2024, and will include discussions of recent developments within the company. Tim Dyer and Dr. Robert Lütjens will also engage in one-on-one meetings with attendees during the event, highlighting the company's focus on allosteric modulation in drug development, particularly for neurological disorders.
Read more →ADXNAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
Addex Therapeutics has announced an At-The-Market Offering Agreement with H.C. Wainwright & Co. LLC, allowing the company to potentially raise up to $2.1 million through the sale of American Depositary Shares (ADSs). This agreement provides flexibility for the company in managing its sales, although it is not obligated to proceed with any. The current market conditions may present challenges for the offering, posing some risk to the potential success of this financing initiative.
Read more →ADXNAddex to Present at the Swiss Equities Baader Conference
Addex Therapeutics has announced that Dr. Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference in Bad Ragaz, Switzerland, from January 10-12, 2024. During his presentation on January 11, he will provide updates on the company's corporate strategies and discuss advancements in their CNS pipeline. Dr. Lütjens will also be available for one-on-one meetings throughout the conference, allowing for direct engagement with stakeholders.
Read more →ADXNAddex to Present at Biotech Showcase™ 2024
Addex Therapeutics announced that CEO Tim Dyer will present an update at the Biotech Showcase 2024 in San Francisco. The presentation will cover recent advancements in the company's pipeline focused on CNS disorders, including the Phase 2 trial of ADX71149 for epilepsy and the evaluation of dipraglurant for post-stroke recovery. The company is focused on developing innovative allosteric modulators for various neurological conditions and will also discuss their strategic partnerships.
Read more →ADXNADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements 2 Unaudited Interim Condensed Consolidated Balance Sheets as of
Addex Therapeutics Ltd released its unaudited interim condensed consolidated financial statements, detailing the financial performance as of June 30, 2023. This includes balance sheets and various financial metrics, providing insight into the company’s financial standing. The document outlines aspects like treasury shares and other financial assets, but no major developments or significant changes were noted.
Read more →ADXNAddex Shareholders Approve All Resolutions at Extraordinary General Meeting
Addex Therapeutics announced that shareholders approved all board proposals during an Extraordinary General Meeting held on December 19, 2023. The approved resolutions include an increase in the capital band and conditional share capital, along with amendments to the Articles of Association. This decision was supported by a significant majority of shareholders, representing 30.07% of the company's outstanding capital. The company focuses on allosteric modulation-based drug discovery for neurological disorders.
Read more →ADXNAddex Creates Treasury Shares
Addex Therapeutics announced the issuance of 15.3 million new shares, fully subscribed by its subsidiary, Addex Pharma S.A. This move is intended to strengthen the company's treasury share pool and provide future financing flexibility. CEO Tim Dyer emphasized the importance of this strategy as Addex progresses its drug development initiatives, including the upcoming results from the Phase 2 study of ADX71149 for epilepsy in mid-2024. The company continues to advance multiple preclinical programs and partnerships.
Read more →ADXNAddex Reports Q3 2023 Financial Results and Provides Corporate Update
Addex Therapeutics has reported its Q3 2023 financial results alongside a corporate update, underlining several key advancements in its product pipeline. Notably, the ADX71149 Phase 2 epilepsy study has completed patient recruitment, with results anticipated in Q2 2024. The company also secured a €4 million grant for its mGlu2 NAM cognition program. However, despite some financial improvements, Addex's cash reserves have diminished, and R&D expenses continue to be substantial.
Read more →ADXNAddex Convenes Extraordinary General Meeting
Addex Therapeutics has announced the convening of an Extraordinary General Meeting scheduled for December 19, 2023, in Geneva, Switzerland. The agenda will include discussions on increasing capital and conditional capital as outlined in the company’s Articles of Association. The meeting is significant for stakeholders, as it may influence the company's future financial strategies and business development. Addex is engaged in innovative drug development focusing on allosteric modulators for neurological disorders.
Read more →ADXNAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
Addex Therapeutics has announced the upcoming release of its third quarter 2023 financial results, scheduled for November 29, 2023. During this event, CEO Tim Dyer and other key executives will offer a business update and a review of the company's product pipeline. Addex focuses on developing allosteric modulators for neurological disorders and is currently advancing multiple clinical programs. The conference will allow attendees to engage with top management and gain insights into the company's strategic direction.
Read more →ADXNAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Addex Therapeutics announced the completion of patient recruitment for the Phase 2 clinical study of ADX71149, a treatment for epilepsy. The last patient has been randomized in Cohort 2, with top line results expected in the second quarter of 2024. The study, conducted in partnership with Janssen Pharmaceuticals, aims to evaluate the efficacy and safety of ADX71149 in combination with established treatments for patients with focal onset seizures. An independent review committee previously recommended the continuation of the study, reflecting positive early findings.
Read more →ADXNAddex Regains Nasdaq Listing Compliance
Addex Therapeutics, a clinical-stage pharmaceutical company, has announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per ADS. The notification from Nasdaq confirms that Addex meets all necessary criteria for continued listing after initially being warned about non-compliance in May 2023. Achieving compliance is seen as a positive development for the company, ensuring its status on the Nasdaq and maintaining investor confidence.
Read more →ADXNAddex Announces Participation in the Bio-Europe 2023 Conference
Addex Therapeutics has announced its participation in the Bio-Europe 2023 Conference scheduled for November 6-8, 2023, in Munich, Germany. The Chief Executive Officer, Tim Dyer, along with Dr. Mikhail Kalinichev, Head of Translational Science, will attend the event and will offer a corporate update through a pre-recorded presentation. They will also be available for one-on-one meetings with registered participants, enhancing opportunities for investor engagement.
Read more →ADXNAddex Completes ADS Ratio Change
Addex Therapeutics has announced a change to its American Depositary Shares (ADS) to ordinary share ratio, effective October 23, 2023. The new ratio will shift from 1 ADS to 6 ordinary shares to 1 ADS to 120 ordinary shares, effectively functioning as a reverse ADS split. This adjustment is intended to help the company comply with Nasdaq's minimum bid price requirement and will not affect the company's ordinary shares or the percentage equity interest of ADS holders. The change will be applied uniformly across all ADS holders, ensuring no fractional ADSs are issued in the process.
Read more →ADXNAddex Announces Plan to Implement ADS Ratio Change
Addex Therapeutics announced a plan to change the ratio of its American Depositary Shares (ADSs) to ordinary shares, moving from a ratio of 1 ADS to 6 ordinary shares to a new ratio of 1 ADS to 120 ordinary shares. This change, which will take effect around October 23, 2023, is intended to help the company comply with Nasdaq’s minimum bid price requirement. As part of this process, existing ADS holders will be automatically exchanged into new ADSs without the need for any action on their part. Despite expectations that the ADS trading price may increase, there are no guarantees regarding price outcomes after the ratio change.
Read more →ADXNAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
Addex Therapeutics has announced that it has led a consortium awarded a €4 million Eurostars grant to advance its mGlu2 receptor negative allosteric modulator program for mild neurocognitive disorder (mNCD). This grant will help the consortium, which includes partners from South Korea, the Netherlands, and the UK, to develop clinical candidates suitable for IND-enabling studies. The mGlu2 NAM program aims to address the unmet medical needs associated with mNCD, which affects a significant portion of the elderly population.
Read more →ADXNAddex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
Addex Therapeutics announced that CEO Tim Dyer will attend the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, in New York. Dyer will deliver a pre-recorded corporate presentation providing updates on Addex's progress. The presentation will be available on-demand. Additionally, Dyer will be available for virtual one-on-one meetings during the conference, highlighting continued engagement with investors.
Read more →ADXNAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Addex Therapeutics announced significant progress in its Phase 2 clinical study for ADX71149, a treatment for epilepsy. Cohort 1 has been completed, and 80% of patients for Cohort 2 have been recruited. Results concerning the efficacy, safety, and tolerability of ADX71149 in combination with existing epilepsy medications are expected by Q2 2024. This study is seen as vital in addressing the urgent need for more effective epilepsy treatments.
Read more →ADXNAddex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
Addex Therapeutics has announced promising findings from a landmark study published in the journal Brain, which highlights the role of mGlu5 receptor negative allosteric modulators (NAMs) in enhancing functional recovery following strokes. The research indicates that dipraglurant, a selective mGlu5 NAM, effectively restores lost neurological functions in preclinical models. Consequently, Addex plans to advance dipraglurant into Phase 2 clinical studies, given the critical need for novel therapies in post-stroke recovery. The findings suggest that targeting mGlu5 may facilitate brain plasticity, vital for restoring function in stroke patients.
Read more →ADXNAddex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
Addex Therapeutics reported its financial results for the first half of 2023, highlighting continued progress in its ADX71149 Phase 2 epilepsy clinical study, which remains on track following a supportive interim review. The partnership with Indivior has been extended to June 2024, with additional research funding secured. Financially, the company saw a reduction in net loss, attributed to decreased research and development expenses. However, cash and cash equivalents have decreased year-over-year, signaling ongoing financial pressures despite operational advancements.
Read more →ADXNAddex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
Addex Therapeutics, a clinical-stage pharmaceutical company, announced it will release its Half-Year 2023 Financial Results on August 10, 2023. The company plans to host a teleconference and webcast at 16:00 CEST for stakeholders to receive a business update and review its product pipeline. Notably, Addex is advancing its lead candidate, ADX71149, which is currently in a Phase 2 clinical trial for epilepsy, reflecting the company's ongoing commitment to drug development.
Read more →ADXNAddex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
Addex Therapeutics has announced an extension of its collaboration with Indivior PLC for the discovery of GABAB positive allosteric modulators (PAM) aimed at treating substance use disorder until June 30, 2024. Indivior has committed CHF 2.7 million to support this extended collaboration. The partnership reflects solid progress in developing effective GABAB PAM candidates. Addex retains exclusive rights to advance its independent GABAB PAM program focusing on chronic cough treatment.
Read more →ADXNAddex mGlu2PAM Demonstrates Potential in Substance Use Disorder
Addex Therapeutics has announced promising findings regarding the use of mGlu2 positive allosteric modulators (PAMs) in the treatment of opioid use disorder. Data published in Neuropharmacology indicates that the drug significantly reduces oxycodone self-administration in preclinical models. The study explores the modulation of glutamate activity as a means to alleviate drug-seeking behaviors. This research suggests that mGlu2 PAMs could become a valuable therapeutic option in addressing prescription opioid abuse.
Read more →ADXNAddex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Addex Therapeutics received a notification from Nasdaq regarding a deficiency in its minimum bid price for American Depositary Shares, which closed below $1.00 for 30 consecutive days. The company has a compliance period of 180 calendar days to address this issue and regain compliance. During this time, if the share price rises to $1.00 or more for ten consecutive days, the deficiency will be resolved. Addex's operations remain unaffected, and it is taking steps to regain compliance.
Read more →ADXNAddex Reports Q1 2023 Financial Results and Provides Corporate Update
Addex Therapeutics reported its Q1 2023 financial results, highlighting the continuation of the Phase 2 study for ADX71149 after a positive review by the independent review committee. Financial data showed a significant improvement in reducing operating loss to CHF 2.4 million compared to the previous year. However, the company faced a substantial decrease in cash reserves year over year. As of March 31, 2023, cash and equivalents fell to CHF 5.6 million, raising concerns about liquidity moving forward.
Read more →ADXNAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
Addex Therapeutics announced that the Phase 2 epilepsy clinical study for ADX71149 has been recommended to continue by an Independent Interim Review Committee. This follows the review of data from Part 1 of Cohort 1, showing promising results regarding the safety and tolerability of the drug. The study, conducted in collaboration with Janssen Pharmaceuticals, aims to evaluate the efficacy of ADX71149 in patients with focal onset seizures. Recruitment for Cohort 2 has begun, and patients may have the option to continue in an extension study assessing long-term efficacy and safety.
Read more →ADXNAddex Convenes Annual General Meeting 2023
Addex Therapeutics announced the date for its Annual General Meeting on May 31, 2023, in Geneva, Switzerland. The meeting will cover various agenda items, including the approval of financial statements, re-elections for board members, and amendments to the company's articles of association. Notably, the event will also address compensation details for the board and executive management. This AGM marks a significant opportunity for shareholders to engage with the company's governance and future direction.
Read more →ADXNAddex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
Addex Therapeutics has announced that it will release its Q1 2023 financial results on May 11, 2023, followed by a conference call featuring CEO Tim Dyer and Head of Discovery Robert Lütjens discussing the company’s product pipeline. This teleconference will provide an update for investors, analysts, and media, emphasizing the company's focus on allosteric modulation-based drug discovery. Addex is noted for its development of therapies for neurological disorders, including its lead drug candidate focused on epilepsy.
Read more →ADXNAddex Completes $5.0 Million Equity Financing
Addex Therapeutics has completed a $5 million equity financing with a significant institutional investor, issuing nearly 8 million shares and associated warrants. The funds will be utilized to enhance its allosteric modulator drug candidates and support general corporate needs. The financing is expected to provide a cash runway through the second quarter of 2024, enabling the company to meet important milestones in its collaborations with Janssen and Indivior. Additionally, certain existing warrants were amended to lower their exercise price as part of this agreement.
Read more →ADXNAddex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
Addex Therapeutics announced the publication of data demonstrating the efficacy of dipraglurant on motor and non-motor symptoms in Parkinson's disease. The results from a Phase 2a study indicate that dipraglurant, an mGlu5 negative allosteric modulator, positively impacts symptoms such as anxiety and depression in addition to levodopa induced dyskinesia. Following oral administration, dipraglurant crossed the blood-brain barrier and exhibited significant effects in various rodent models. The company is now exploring future development paths for dipraglurant to enhance the quality of life for Parkinson's patients.
Read more →ADXNAddex Raises $5.0 Million in Equity Financing
Addex Therapeutics Ltd announced a definitive agreement to raise $5 million in equity financing by issuing shares and warrants to a leading institutional healthcare investor. The proceeds from this offering will support the advancement of its drug candidates and general corporate purposes. The transaction is anticipated to finalize around April 5, 2023, subject to standard closing conditions. Additionally, Addex is modifying previously issued warrants to enhance their terms, which involves reducing their exercise prices.
Read more →ADXNAddex Reports Full Year 2022 Financial Results and Provides Corporate Update
Addex Therapeutics reported its financial results for the year 2022, highlighting a net loss of CHF 20.8 million, attributed to increased expenses and decreased income. The company successfully completed part 1 of the Phase 2 study for its epilepsy candidate ADX71149, with an interim review expected in early Q2 2023. Addex also emphasized ongoing progress in its preclinical programs and partnerships, despite a notable decline in cash reserves and an overall operating loss for the year. Management remains focused on securing collaborations to enhance financial stability and advance its drug development pipeline.
Read more →ADXNAddex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
Addex Therapeutics will announce its full-year 2022 financial results and provide a corporate update on March 30, 2023. The conference call will include insights from CEO Tim Dyer and Head of Discovery Robert Lütjens, highlighting the company's product pipeline. Interested participants need to register in advance to receive access details. Addex focuses on developing allosteric modulators for neurological disorders, with promising findings in its clinical programs.
Read more →ADXNAddex Announces Upcoming Conferences it will participate for H1 2023
Addex Therapeutics has announced its participation in several key conferences during the first half of 2023, including Bio-Europe Spring and Swiss Biotech Day. The conferences will provide opportunities for Addex's management team to meet with investors and stakeholders. The company continues to focus on its development of allosteric modulators for neurological disorders, which may offer significant therapeutic advantages. This strategic engagement at conferences aims to enhance collaboration and visibility in the biopharma sector.
Read more →ADXNAddex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
Addex Therapeutics has announced the completion of enrollment in Part 1 of its Phase 2 study for ADX71149, a treatment for epilepsy. Conducted in collaboration with Janssen Pharmaceuticals, the study aims to evaluate the efficacy and safety of ADX71149 in patients experiencing focal onset seizures with inadequate response to existing therapies. Data from this phase will be reviewed by an independent interim review committee to ensure the study remains blinded. The outcome of this review will inform the next steps in the development program, expected by the end of Q1 2023.
Read more →ADXNAddex Provides Corporate Update and Financial Guidance
Addex Therapeutics provided a corporate update outlining its financial status and pipeline progress. The company announced having CHF 7.0 million in cash to sustain operations until the third quarter of 2023, while indicating ongoing collaborations with Janssen and Indivior to further advance their drug development programs. Notably, the Phase 2 study for ADX71149, its epilepsy treatment, is on track for completion within the first quarter of 2023. The company also expressed intent to explore new strategic partnerships for the development of dipraglurant, targeting multiple therapeutic areas.
Read more →ADXNAddex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
Addex to receive USD 1 million in additional research funding Collaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stag
Read more →ADXNAddex Reports Q3 2022 Financial Results and Provides Corporate Update
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022 Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and Nasdaq: AD
Read more →ADXNAddex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its third quarter 2022 financial results on Friday,
Read more →ADXNAddex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd An
Read more →ADXNAddex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022 CHF4.6M equity financing in July extends cash runway into Q2 2023 Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, Au
Read more →ADXNAddex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceuti
Read more →ADXNAddex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2022 financial results on Thursday, Au
Read more →ADXNAddex Completes $4.2 Million Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland
Addex Completes $4.2 Million Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and
Read more →ADXNAddex Completes $4.2 Million Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has complet
Read more →ADXNAddex Raises $4.2 million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered
Read more →ADXNAddex Completes Reduction in Nominal Value of Shares
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the reduction of the n
Read more →ADXNAddex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based d
Read more →ADXNAddex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a s
Read more →ADXNAddex Announces Participation in the H.C. Wainwright Global Investment Conference
Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright
Read more →ADXNAddex Announces Participation in the 22nd Bio€quity Europe Conference
Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Bio
Read more →ADXNAddex Reports Q1 2022 Financial Results
CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022 Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expected to report data in H1 2023 Janssen led
Read more →ADXNAddex to Present at the Swiss Biotech Day 2022
Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2022 ta
Read more →ADXNAddex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the B. Riley Securities Neuro
Read more →ADXNAddex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and deve
Read more →ADXNAddex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical com
Read more →ADXNAddex Convenes Annual General Meeting 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual Genera
Read more →ADXNAddex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at both the Bio-Europe Spring 202
Read more →ADXNAddex Reports Full Year 2021 Financial Results and Provides Corporate Update
CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021 Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expected to report data in H1 2023 Janssen l
Read more →ADXNAddex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022
Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2021 financial results on Thursday, M
Read more →ADXNAddex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums
Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at both the 3rd Annual Europea
Read more →ADXNAddex to Present at the Swiss Equities Baader Virtual Conference
Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Equities Baader Vi
Read more →ADXNAddex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright BIOCONNECT
Read more →ADXNAddex Raises $10.0 Million in Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland
Addex Raises $10.0 Million in Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discover
Read more →ADXNAddex Raises $10.0 Million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has ent
Read more →ADXNAddex Provides Year End Pipeline Development Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharm
Addex Provides Year End Pipeline Development Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and d
Read more →ADXNAddex Provides Year End Pipeline Development Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided an update on progress
Read more →ADXNAddex to Present at the Virtual German Equity Forum
Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery – Biology, Dr Robert Lüt
Read more →ADXNAddex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mod
Read more →ADXNAddex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual
Read more →ADXNAddex Reports Q3 2021 Financial Results and Provides Corporate Update
CHF15.5M ($16.6M) of cash and cash equivalents at September 30, 2021 Cash used in Q3 2021 of CHF2.6M Dipraglurant Phase 2 blepharospasm clinical trial Initiated Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease on track Janssen led ADX71149 Phase
Read more →ADXNAddex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021
Geneva, Switzerland, November 1, 2021 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its Q3 2021 financial results on Thursday, Novem
Read more →ADXNAddex to Present at the Investors’ Day hosted by Voxia Communication
Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors’ Day hosted by Vox
Read more →ADXNAddex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
Geneva, Switzerland, October 4, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Ch
Read more →ADXNAddex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a
Read more →ADXNAddex to Present at the Cantor Global Healthcare 2021 Conference
Geneva, Switzerland, September 29, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conferenc
Read more →ADXNAddex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Inves
Read more →ADXNAddex to Present at the Swiss Biotech Day
Geneva, Switzerland, September 2, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day,
Read more →ADXNAddex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M) Pivotal dipraglurant PD-LID study initiated Janssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149 Dipraglurant blepharospasm study on track to start in Q3 2021 Completed $11.5M f
Read more →ADXNAddex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thu
Read more →ADXNAddex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the app
Read more →ADXNAddex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022 Geneva, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmac
Read more →ADXNAddex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Confe
Read more →ADXNAddex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery tools Addex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in pr
Read more →ADXNAddex Establishes At-The-Market ADS Equity Sale Program
Geneva, Switzerland, June 30, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into a sales agreement with Cantor Fitzgerald & Co. (Ca
Read more →ADXNAddex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3
Read more →ADXNAddex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the first
Read more →ADXNAddex to Participate at the Benchmark Company Healthcare House Call Conference
Geneva, Switzerland, May 24, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will participate at the virt
Read more →ADXNAddex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder Geneva, Switzerland, May 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based d
Read more →ADXNAddex Convenes Annual General Meeting 2021
Geneva, Switzerland, May 14, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday 16 June
Read more →ADXNADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as at
ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as at March 31, 2021 and December 31, 2020 2 Unaudited Interim C
Read more →ADXNAddex Reports Q1 2021 Financial Results and Provides Corporate Update
Strong cash and cash equivalents position at March 31, 2021 of CHF25.2M ($26.7M) Completed $11.5M fundraising in January 2021 Three clinical studies in neurology programs remain on track to start during Q2 2021 Neurology programs aimed at large underserved market opportunities
Read more →ADXNAddex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
Geneva, Switzerland, May 3, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2021 financial results on Wednesday May
Read more →ADXNAddex to Present at the 20th Annual Needham Virtual Healthcare Conference
Geneva, Switzerland, April 13, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 20
Read more →ADXNAddex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
Geneva, Switzerland, April 8, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has filed a registration statement on Form F-3 with the
Read more →ADXNAddex Reports Full Year 2020 Financial Results and Provides Corporate Update
Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021 Three clinical studies in neurology programs expected to start during H1 2021 Clinical stage neurology programs aimed at
Read more →ADXNAddex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2020 financial results on Thursday March 11, 2021.
Read more →ADXNAddex to Present at the H.C. Wainwright Global Life Sciences Conference
Geneva, Switzerland, March 4, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the H.C
Read more →ADXNAddex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 m
Read more →ADXNAddex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder
Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, t
Read more →ADXNAddex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Geneva, Switzerland, January 21, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today
Read more →ADXNAddex to Present at the Baader Helvea Swiss Equities Conference
Geneva, Switzerland, January 12, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to par
Read more →ADXNAddex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the successful completion of the previously announced global
Read more →ADXNAddex Announces Pricing of $10.0 Million Global Offering
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 r
Read more →ADXNAddex Announces Filing of Registration Statement for Proposed Public Offering of Securities
Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Sec
Read more →ADXNAddex Reports Q3 2020 Financial Results and Provides Corporate Update
Geneva, Switzerland, November 3, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its third quarter financial results and provided an update on cor
Read more →ADXNAddex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
Geneva, Switzerland, November 2, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of the agreement signed with Indivior PLC (LON: INDV) in January
Read more →ADXNADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 3rd, 2020
Geneva, Switzerland, November 2, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its Q3 2020 financial results, provide a business update and review its pipeline during a t
Read more →ADXNAddex to Present at the Investora Conference
Geneva, Switzerland, September 23, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that Tim Dyer, Chief Executive Officer, is scheduled to participate at the Investora Co
Read more →ADXNAddex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference
Geneva, Switzerland, September 14, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that Tim Dyer, Chief Executive Officer, is scheduled to participate at the Virtual H.C.
Read more →ADXNAddex Therapeutics to Participate at the Biotechgate Digital Partnering Conference
Geneva, Switzerland, August 31, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that that Tim Dyer, Chief Executive Officer, is scheduled to participate at the Biotechgat
Read more →ADXNAddex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling
ADX10061 Previously Demonstrated Favorable Safety and Tolerability in Clinical Studies Geneva, Switzerland, August 27, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and develo
Read more →ADXNADDEX THERAPEUTICS LTD INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as at
ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as at June 30, 2020 and December 31, 2019 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss
Read more →ADXNAddex Reports 2020 Half Year Financial Results and Provides Corporate Update
Geneva, Switzerland, August 12, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its second quarter and half year financial results for the periods
Read more →ADXNAddex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020
Geneva, Switzerland, August 10, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2020 financial results, provide a business update and review its pipeline duri
Read more →ADXNAddex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020
Geneva, Switzerland, August 6, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will participate in the BTIG Virtual Biotechnology
Read more →ADXNAddex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study
Study with JNJ-40411813 (ADX71149) will treat first epilepsy patients in early 2021 Geneva, Switzerland, June 16, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development
Read more →ADXNAddex Reports Q1 2020 Financial Results and Provides Corporate Update
Geneva, Switzerland, May 20, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its first quarter results for the period ended March 31, 2020 and pro
Read more →ADXNAddex Therapeutics Establishes Scientific Advisory Board
World-leading experts will support our strategic decision-making processes as we continue advancing our pipeline of allosteric modulators Geneva, Switzerland, May 19, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering alloste
Read more →ADXNAddex Reports 2019 Full Year Audited Results and Provides Corporate Update
Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021 Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD program Additional funding of $1.6 million in 2019 from Indivior to support GABAB PAM addiction program D
Read more →ADXNAddex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020
Geneva, Switzerland, April 6, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, will discuss its full year 2019 financial results, provide a business update and re
Read more →ADXNAddex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results Geneva, Switzerland
Addex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results Geneva, Switzerland, March 18, 2020 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug di
Read more →ADXNAddex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results
Geneva, Switzerland, March 18, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that due to the impact of the COVID-19 coronavirus pandemic, the s
Read more →ADXNAddex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020
Geneva, Switzerland, March 13, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, will discuss its full year 2019 financial results, provide a business update and r
Read more →ADXNAddex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board Geneva, Switzerland
Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board Geneva, Switzerland, March 3, 2020 - Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric m
Read more →ADXNAddex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board
Geneva, Switzerland, March 3, 2020 - Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the appointment of one of the world’s leading and most successful neuro
Read more →ADXNAddex Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
Geneva, Switzerland, February 26, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to present a
Read more →ADXNAddex Therapeutics to Ring the Nasdaq Stock Market Closing Bell
Geneva, Switzerland and New York, February 3, 2020 - Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, CEO, will ring the Nasdaq Closing Bell today a
Read more →ADXNAddex Starts Trading American Depositary Shares on Nasdaq Under Ticker ADXN
Geneva, Switzerland, January 29, 2020 -- Addex Therapeutics Ltd (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the listing of American Depositary Shares (ADSs) representing its ordinary s
Read more →ADXNAddex Provides Trading Update and Completes 2019 with Cash Position of CHF31.5 million
Geneva, Switzerland, January 13, 2020 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that it completed 2019 with CHF31.5 million of cash and cash equivalents, and in 2019 used net cash in operations
Read more →ADXNAddex to Attend 38th Annual J.P. Morgan Healthcare Conference
Geneva, Switzerland, January 8, 2020 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that members of its management team: CEO, Tim Dyer, CMO, Roger Mills and head of drug discovery biology, Robert Lut
Read more →ADXNAddex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program
Geneva, Switzerland, December 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Indivior PLC (LON: INDV) will provide Addex with a second additional $800,000 in 2019 to accelerate research
Read more →ADXNADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES
Geneva, Switzerland, 18 December 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it has publicly filed its registration statement on Form F-1 with the United States
Read more →ADXNAddex: Van Leeuwenhoeck Issues Update Equity Research Report
Geneva, Switzerland, December 3, 2019 – Addex Therapeutics (SIX: ADXN), a clinical-stage leading allosteric modulation-based drug discovery and development company, today announced the independent life science equity research company, Van Leeuwenhoeck, has issued an updated equit
Read more →ADXNAddex to Attend Jefferies 2019 London Healthcare Conference
Geneva, Switzerland, November 13, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer, Tim Dyer, will be attending the Jefferies 2019 London Healthcare Conference, London
Read more →ADXNAddex to Attend BIO-Europe Conference in Hamburg
Geneva, Switzerland, November 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that Chief Executive Officer Tim Dyer will provide a corporate update during a presentation at the 25th Annual BI
Read more →ADXNAddex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program
Indivior Investment Reflects Progress Towards Clinical Evaluation and Validates Power of Allosteric Platform Geneva, Switzerland, October 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that
Read more →ADXNAddex Reports 2019 Half-Year Financial Results and Provides Corporate Update
Geneva, Switzerland, September 30, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today reported its half-year financial results for the period ended June 30, 2019 and provided an update on corporate activities
Read more →ADXNADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019
Geneva, Switzerland, September 25, 2019 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2019 financial results, provide a business update and review its pipeline during a teleconf
Read more →ADXNAddex Therapeutics Submits Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Shares
Geneva, Switzerland, 24 September 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it has confidentially submitted a draft registration statement on Form F-1 to the U
Read more →ADXNAddex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)
Geneva, Switzerland, July 9, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will lead a consortium for the development of small-molecule negative allosteric modulators (NAMs)
Read more →ADXNAddex Annual General Meeting Scheduled for June 19, 2019
Geneva, Switzerland, May 28, 2019 – Addex Therapeutics (SIX: ADXN) announced today that its Annual General Meeting will take place on Wednesday, June 19, 2019, at 11:00am at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). 1. Approval of the Annua
Read more →ADXNAddex Increases Issued Share Capital and Creates Treasury Shares
Geneva, Switzerland, May 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its capital from 28,564,031 to 32,848,635 through the issue of 4,284,604 new register
Read more →ADXNAddex to Present at the 28th Medtech Investing Europe Conference
Geneva, Switzerland, May 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will give a corporate presentation at the 28th Medtech Investing Europe conference held M
Read more →ADXNAddex to Present During the Swiss Biotech Day
Geneva, Switzerland, May 6, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present the company at the Swiss Biotech Day, held May 7, 2019 at the Congress Cente
Read more →ADXNAddex Reports 2018 Full Year Audited Results and Provides Corporate Update
Robust cash position of CHF41.7 million providing runway through 2021 Dipraglurant on track to start pivotal registration study in PD-LID by end of year Strengthened team of clinical and preclinical experts Developing broad allosteric modulator pipeline addressing multiple CNS
Read more →ADXNAddex to Announce 2018 Full Year Audited Results on April 30, 2019
Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its full-year audited results for the year ended December 31, 2018 on April 30, 2019
Read more →ADXNAddex to Participate in the BIOEurope Spring Conference
Geneva, Switzerland, March 21, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer and Head of Discovery Biology, Dr. Robert Lütjens, will be attending the BIOEurope Spr
Read more →ADXNAddex to Present at the Cowen 39th Annual Health Care Conference on March 13, 2019
Geneva, Switzerland, 11 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the company’s CEO, Tim Dyer, will give a presentation at the Cowen 39th Annual Health Care Conference
Read more →ADXNAddex Trading Update in Accordance with Art. 53 of the SIX Listing Rules (Ad hoc publicity)
Geneva, Switzerland, 8 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today an unaudited operating loss of CHF1.6 milion for the financial year 2018. Key Financials for FY 2018 (Unau
Read more →ADXNAddex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441
Geneva, Switzerland, 14th February 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, and Indivior PLC (LON: INDV) announced today that they will accelerate the optimization and further development of ad
Read more →ADXNAddex Trading Update: Completes 2018 with Strong Cash Position
Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed the year 2018 with CHF41.7 million of cash and cash equivalence, and a net operat
Read more →ADXNAddex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14
Geneva, Switzerland, 22 November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the independent life science equity research company, Van Leeuwenhoeck, has issued an equity resea
Read more →ADXNAddex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference
Geneva, Switzerland, 12th November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will provide a corporate update at the upcoming Biotech and Money Inv€$tival Show
Read more →ADXNAddex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), AD
Read more →ADXNAddex to Present at the Sachs 18th Annual Biotech in Europe Forum
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will participate in the 18th Annual Biotech in Europe Forum in Basel (4-5 October) or
Read more →ADXNAddex Reports 2018 Half-Year Financial Results and Provides Corporate Update
Geneva, Switzerland, 28 September 2018 – Addex Therapeutics (SIX: ADXN), a company pioneering allosteric modulation-based drug discovery and development, today reported its half-year financial results for the period ended 30 June 2018 and provided an update on corporate activitie
Read more →ADXNADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR
Geneva, Switzerland and London, UK, 25 September 2018 – Addex Therapeutics (SIX: ADXN), a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders, announced today that it has been recognised
Read more →ADXNAddex to Present at the Investora Zurich Conference on 27 September
Geneva, Switzerland, 25 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investora Zurich conference at 12:45 CET on 27 September 2018
Read more →ADXNAddex ADX10061 Receives 1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust
Geneva, Switzerland, 20 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has joined the Human Drug and Brain Research (THuNDR2) initiative. THuNDR2 is a collaboration
Read more →ADXNAddex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
Preclinical and Adhoc Clinical Data Published in Molecular Psychiatry Geneva, Switzerland, 4 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today publication of a study demonstra
Read more →ADXNAddex Reports 2017 Full Year Results and Provides Corporate Update
Accessibility: Skip TopNav Addex Reports 2017 Full Year Results and Provides Corporate Update April 30, 2018 01:00 ET Robust cash position of CHF45 million following capital raise in Q1 2018 Major global licensing agreement with Indivior in addiction Geneva, Switzerland, 30
Read more →ADXNAddex Sucessfully Raises CHF40 million in Capital Increase
Accessibility: Skip TopNav Addex Sucessfully Raises CHF40 million in Capital Increase March 29, 2018 01:00 ET Geneva, Switzerland, 29 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today th
Read more →ADXNAddex Shareholders Approved all Board Proposals at Extraordinary General Meeting
Accessibility: Skip TopNav Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting March 19, 2018 02:00 ET Geneva, Switzerland, 19 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorde
Read more →ADXNAddex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process
Accessibility: Skip TopNav Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process March 05, 2018 01:00 ET Geneva, Switzerland, 5 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral al
Read more →ADXNAddex Publishes Extraordinary General Meeting Invitation
Accessibility: Skip TopNav Addex Publishes Extraordinary General Meeting Invitation February 23, 2018 01:00 ET Geneva, Switzerland, 23 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced toda
Read more →ADXNAddex Launches CHF40 million Capital Increase with Commitment from Specialist US Healthcare Investors
Proceeds will extend cash runway through 2022 and fund dipraglurant through the first pivotal registration study in PD-LID Geneva, Switzerland, 15 February 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, anno
Read more →ADXNAddex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management
Accessibility: Skip TopNav Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management February 07, 2018 01:00 ET Geneva, Switzerland, 7 February 2018 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-ba
Read more →ADXNAddex Provides Key Financial Indicators and Trading Update
Accessibility: Skip TopNav Addex Provides Key Financial Indicators and Trading Update February 05, 2018 01:00 ET Cash position of CHF6.5 million as of 31 January 2018 Geneva, Switzerland, 5 February 2018 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteri
Read more →ADXNAddex Therapeutics Equity Research Report Update Issued by valuationLAB
Accessibility: Skip TopNav Addex Therapeutics Equity Research Report Update Issued by valuationLAB January 08, 2018 01:00 ET Report estimates a current value of ADXN of CHF 12.5 per share Geneva, Switzerland, 8 January 2018 - Addex Therapeutics (SIX: ADXN) announced today tha
Read more →ADXNAddex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments
Accessibility: Skip TopNav Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments January 03, 2018 01:00 ET Addex Receives $5 Million Upfront, Potential Milestones of $330 Million and Tiered Royalties up to Double Digit A
Read more →ADXNAddex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder
Accessibility: Skip TopNav Addex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder October 03, 2017 01:30 ET Geneva, Switzerland, 3 October 2017 - Addex Therapeut
Read more →ADXNAddex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results September 26, 2017 01:00 ET Geneva, Switzerland, 26 September 2017 - Addex Therapeutics (SIX: ADXN) announced today its first half 2017 operating highlights and fin
Read more →ADXNAddex Makes Changes to Executive Management Team
Accessibility: Skip TopNav Addex Makes Changes to Executive Management Team September 18, 2017 01:00 ET Geneva, Switzerland, 18 September 2017 - Addex Therapeutics (SIX: ADXN) announced today that Robert Lutjens, Head of Discovery will join the Executive Management Team and ta
Read more →ADXNAddex Shareholders Approved all Board Proposals at 2017 Annual General Meeting
Accessibility: Skip TopNav Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting June 23, 2017 01:00 ET Roger Mills elected to the Addex Board of Directors Geneva, Switzerland, 23 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its sh
Read more →ADXNAddex Annual General Meeting Scheduled for 22 June 2017
Accessibility: Skip TopNav Addex Annual General Meeting Scheduled for 22 June 2017 June 06, 2017 01:00 ET Geneva, Switzerland 6 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 22 June 2017, at 11:00am at
Read more →ADXNAddex ADX71441 Demonstrates Preclinical Analgesic Effects
Accessibility: Skip TopNav Addex ADX71441 Demonstrates Preclinical Analgesic Effects May 09, 2017 01:00 ET Support Potential of ADX71441 to treat Irritable Bowel Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics
Read more →ADXNAddex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology
Accessibility: Skip TopNav Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology May 04, 2017 01:00 ET Study Conducted in Collaboration with National Institute on Alcohol Abuse and Alcoholism Geneva, Switzerland, 4
Read more →ADXNAddex Therapeutics Provides Corporate Update and Reports 2016 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results April 05, 2017 01:00 ET Geneva, Switzerland, 5 April 2017 - Addex Therapeutics (SIX: ADXN) today provided a corporate update and reported full-year 2016 financial results
Read more →ADXNAddex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018
Geneva, Switzerland, 28 February 2017 - Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF3.0 million through a private placement in which 1.5 million treasury shares were placed at CHF2 per share. The private placement was led by Herculis Par
Read more →ADXNAddex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
Accessibility: Skip TopNav Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia February 27, 2017 01:00 ET Geneva, Switzerland, 27 February 2017 - Addex Therapeutics (SIX: ADXN) announced today the publication of a study demonstrating the anti-ep
Read more →ADXNAddex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
Accessibility: Skip TopNav Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases February 06, 2017 01:00 ET Geneva, Switzerland, 6 February 2017 - Addex Therapeutics (SIX: ADXN) announced
Read more →ADXNAddex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease
Accessibility: Skip TopNav Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson's Disease January 31, 2017 01:00 ET Geneva, Switzerland, 31 January 2017 - Addex Therapeutics (SIX: ADXN) announced today that The Michael
Read more →ADXNAddex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor demonstrated statistically significant efficacy in a highly translational preclinic
Read more →ADXNAddex ADX71441 Pharmacological Profile Published in Neuropharmacology
Accessibility: Skip TopNav Addex ADX71441 Pharmacological Profile Published in Neuropharmacology December 13, 2016 01:00 ET Geneva, Switzerland, 13 December 2016 - Addex Therapeutics (SIX: ADXN), announced today that the pharmacological profile of ADX71441, gamma-aminobutyric
Read more →ADXNAddex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer
Accessibility: Skip TopNav Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer November 28, 2016 01:00 ET Dr Mills adds extensive expertise in Parkinson's disease drug development and commercialization Geneva, Switzerland, 28 Nove
Read more →ADXNAddex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia
Accessibility: Skip TopNav Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia October 17, 2016 01:00 ET Company Expects to Initiate Study in Fourth Quarter of 2016 Trial Design Developed in Collaboration with Emory Univer
Read more →ADXNAddex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
Accessibility: Skip TopNav Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction October 11, 2016 01:00 ET Geneva, Switzerland, 11 October 2016 - Addex Therapeutics (SIX: ADXN) announce
Read more →ADXNAddex Therapeutics Reports First Half 2016 Operating Highlights and Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports First Half 2016 Operating Highlights and Financial Results September 30, 2016 01:00 ET Geneva, Switzerland, 30 September 2016 - Addex Therapeutics (SIX: ADXN) announced today its first half 2016 operating highlights and fin
Read more →ADXNAddex Collaborators Published New Data Supporting the Role of Negative Allosteric Modulators of Follicle Stimulating Hormone and Luteinizing Hormone Receptors in Reproductive Health
Accessibility: Skip TopNav Addex Collaborators Published New Data Supporting the Role of Negative Allosteric Modulators of Follicle Stimulating Hormone and Luteinizing Hormone Receptors in Reproductive Health September 20, 2016 01:00 ET Geneva, Switzerland, 20 September 2016 -
Read more →ADXNAddex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.
Accessibility: Skip TopNav Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity. July 27, 2016 01:00 ET Geneva, Switzerland, 27 July 2016 - Addex Therapeutics (SIX: ADXN) announced today that ADX71441, a positive allosteric modul
Read more →ADXNAddex Shareholders Approved all Board Proposals at 2016 Annual General Meeting
Accessibility: Skip TopNav Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting June 24, 2016 01:00 ET Geneva, Switzerland, 24 June 2016 - Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of
Read more →ADXNAddex mGluR4 and mGluR7 Programs Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Accessibility: Skip TopNav Addex mGluR4 and mGluR7 Programs Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases June 13, 2016 01:00 ET Geneva, Switzerland, 13 June 2016 - Addex Therapeutics (SIX:ADXN), announced today the successful comple
Read more →ADXNAddex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction
Accessibility: Skip TopNav Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction June 09, 2016 01:00 ET Geneva, Switzerland, 9 June 2016 - Addex Therapeutics (SIX: ADXN), announced today positive results with ADX71441, a GABAB receptor po
Read more →ADXNAddex Annual General Meeting Scheduled for 23 June 2016
Accessibility: Skip TopNav Addex Annual General Meeting Scheduled for 23 June 2016 June 02, 2016 01:15 ET Geneva, Switzerland 2 June 2016 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 23 June 2016, at 11:00am at
Read more →ADXNAddex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society
Accessibility: Skip TopNav Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society June 02, 2016 01:00 ET Geneva, Switzerland, 2 June 2016 - Addex Therapeutics (SIX: ADXN) announced today that results from
Read more →ADXNAddex Therapeutics Reports 2015 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports 2015 Financial Results April 29, 2016 12:30 ET Geneva, Switzerland, 29 April 2016 - Addex Therapeutics (SIX: ADXN) announced today 2015 financial results. 2015 Financial Highlights Net increase in cash and cash equivalenc
Read more →ADXNAddex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Accessibility: Skip TopNav Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers April 11, 2016 01:00 ET Geneva, Switzerland, 11 April 2016 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulatio
Read more →ADXNAddex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
Accessibility: Skip TopNav Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers March 15, 2016 02:00 ET Geneva, Switzerland, 15 March 2016 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modu
Read more →ADXNAddex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept
Accessibility: Skip TopNav Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept January 11, 2016 01:00 ET Additional analysis underlines the potential significant thera
Read more →ADXNAddex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease
Accessibility: Skip TopNav Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease January 04, 2016 01:00 ET FDA Orphan Drug Status Validates the Potential Therapeutic Use of Dipraglurant in this Rar
Read more →ADXNAddex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
Accessibility: Skip TopNav Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial December 17, 2015 01:00 ET Geneva, Switzerland, 17 December 2015 - Addex Therapeutics (SIX: ADXN), a leading company pi
Read more →ADXNAddex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents
Accessibility: Skip TopNav Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents December 15, 2015 01:00 ET Geneva, Switzerland, 15 December 2015 - Addex Therapeutics (SIX: ADXN), a leading compan
Read more →ADXNAddex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
Accessibility: Skip TopNav Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis December 09, 2015 01:00 ET Geneva, Switzerland, December 9, 2015 - Addex Therapeutics (SIX: ADXN), a leading company pio
Read more →ADXNAddex Moves R&D Operations to Geneva's Campus Biotech
Accessibility: Skip TopNav Addex Moves R&D Operations to Geneva's Campus Biotech December 07, 2015 01:00 ET Geneva, Switzerland, December 7, 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced
Read more →ADXNAddex ADX71441 Included in the NINDS Anticonvulsant Screening Program
Accessibility: Skip TopNav Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program November 25, 2015 01:00 ET Geneva, Switzerland, 25 November 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and devel
Read more →ADXNAddex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
Accessibility: Skip TopNav Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases November 23, 2015 01:00 ET Geneva, Switzerland, 23 November 2015 - Addex Therapeutics (SIX:
Read more →ADXNAddex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
Accessibility: Skip TopNav Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder October 13, 2015 01:00 ET Successful collaboration with the US National Institute for Alcohol Abuse and Alcoholism Geneva, Switzerland, 13 October 20
Read more →ADXNAddex Therapeutics Reports First Half 2015 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports First Half 2015 Financial Results September 30, 2015 01:00 ET Geneva, Switzerland, 30 September 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,
Read more →ADXNAddex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
Accessibility: Skip TopNav Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy September 23, 2015 01:00 ET Geneva, Switzerland, 23 September 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulat
Read more →ADXNAddex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's Disease
Accessibility: Skip TopNav Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson's Disease August 14, 2015 01:00 ET Geneva, Switzerland 14 August 2015 - Addex Therapeutics (SIX:
Read more →ADXNAddex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation
Accessibility: Skip TopNav Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation July 22, 2015 01:00 ET Geneva, Switzerland, 22 July 2015 - Addex Therapeutics (SI
Read more →ADXNAddex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting
Accessibility: Skip TopNav Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting June 12, 2015 01:00 ET Geneva, Switzerland, 12 June 2015 - Addex Therapeutics (SIX: ADXN), a leading company pion
Read more →ADXNAddex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain
Accessibility: Skip TopNav Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain June 03, 2015 01:00 ET Geneva, Switzerland 3 June 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug dis
Read more →ADXNAddex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia
Accessibility: Skip TopNav Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia May 29, 2015 01:00 ET 5th Biennial Workshop on Dystonia "Controversies in Dystonia and Parkinsonism" Rome, 29-30 May 2015 Geneva, Switzerland 29 May 2015 - Addex Th
Read more →ADXNAddex Annual General Meeting Scheduled for 11 June 2015
Accessibility: Skip TopNav Addex Annual General Meeting Scheduled for 11 June 2015 May 27, 2015 09:50 ET Geneva, Switzerland 27 May 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today th
Read more →ADXNAddex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia
Accessibility: Skip TopNav Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia May 07, 2015 01:00 ET Geneva, Switzerland 7 May 2015 - Addex Therapeutics (SIX: ADXN), a leading company
Read more →ADXNAddex Therapeutics Reports 2014 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports 2014 Financial Results April 30, 2015 01:00 ET 2014 Financial Highlights Increased income to CHF0.7 million in 2014 compared to CHF0.1 million in 2013 Reduced operating loss to CHF1.8 million in 2014 compared to CHF14.5 m
Read more →ADXNAddex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017
Accessibility: Skip TopNav Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017 March 09, 2015 02:00 ET Geneva, Switzerland, 9 March 2015 - Addex Therapeutics (SIX: ADXN) announced today that it has raised gross proceeds of CHF2.8 million in
Read more →ADXNAddex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation
Accessibility: Skip TopNav Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation February 23, 2015 01:00 ET Geneva, Switzerland, 23 February 2015 - Addex Therapeutics (SIX:
Read more →ADXNAddex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
Accessibility: Skip TopNav Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death February 19, 2015 01:00 ET Geneva, Switzerland, 19 February 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug
Read more →ADXNAddex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia
Accessibility: Skip TopNav Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia January 19, 2015 01:00 ET Geneva, Switzerland /Chicago, USA, 19 January 2015 - Addex Therapeutics (SIX: AD
Read more →ADXNAddex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update
Accessibility: Skip TopNav Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update January 09, 2015 01:00 ET Geneva, Switzerland, 9 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery
Read more →ADXNAddex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder
Accessibility: Skip TopNav Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder January 07, 2015 01:00 ET Geneva, Switzerland, 7 January 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery a
Read more →ADXNAddex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000
Accessibility: Skip TopNav Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000 December 17, 2014 01:00 ET Geneva, Switzerland, 17 December 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and devel
Read more →ADXNAddex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder
Accessibility: Skip TopNav Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder October 21, 2014 01:00 ET Geneva, Switzerland, 21 October 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering all
Read more →ADXNAddex Therapeutics Reports First Half 2014 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports First Half 2014 Financial Results September 30, 2014 01:00 ET Geneva, Switzerland, 30 September 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development,
Read more →ADXNAddex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
Accessibility: Skip TopNav Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction July 10, 2014 01:00 ET ADX71441 reversed somatic signs of withdrawal in nicotine-dependent mice and reversed hyperalgesia, further supporting the use of GABA-B activation as a
Read more →ADXNAddex Shareholders Approve All Board Proposals at Annual General Meeting
Accessibility: Skip TopNav Addex Shareholders Approve All Board Proposals at Annual General Meeting June 30, 2014 01:00 ET Geneva, Switzerland, 30 June 2014 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and developmen
Read more →ADXNAddex Therapeutics Publishes Annual General Meeting Agenda
Accessibility: Skip TopNav Addex Therapeutics Publishes Annual General Meeting Agenda June 12, 2014 13:08 ET Geneva, Switzerland, 12 June 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual General Meeting Agenda. The Company will hold its Annua
Read more →ADXNAddex Therapeutics Publishes Annual Reports 2013
Accessibility: Skip TopNav Addex Therapeutics Publishes Annual Reports 2013 May 30, 2014 12:00 ET Geneva, Switzerland, 30 May 2014 - Addex Therapeutics (SIX: ADXN) announced today the publication of its Annual Report 2013 in accordance with the notice given in the press releas
Read more →ADXNAddex Therapeutics Reports 2013 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports 2013 Financial Results April 30, 2014 01:00 ET 2013 Financial Highlights Significant reduction in 2013 cash utilization of CHF12.3 million, significantly below guidance of CHF15 million, CHF1.6 million used in second half
Read more →ADXNAddex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms
Accessibility: Skip TopNav Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms February 07, 2014 12:14 ET Geneva, Switzerland, 7 February 2014 - (SIX:ADXN), Addex Therapeutics, a leading co
Read more →ADXNAddex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction
Accessibility: Skip TopNav Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction November 04, 2013 01:00 ET Geneva, Switzerland, 4 November 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based d
Read more →ADXNAddex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Accessibility: Skip TopNav Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression October 29, 2013 02:00 ET On track to report top line results end of Q1 2014 Geneva, Switzerland, 29 October 2013 - Ad
Read more →ADXNAddex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease
Accessibility: Skip TopNav Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease October 03, 2013 01:00 ET Geneva, Switzerland, 3 October 2013 - Addex Therapeutics (SIX: ADXN), a lea
Read more →ADXNAddex Therapeutics First Half 2013 Financial Results
Accessibility: Skip TopNav Addex Therapeutics First Half 2013 Financial Results September 17, 2013 01:05 ET Geneva, Switzerland, 17 September 2013 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announce
Read more →ADXNAddex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors
Accessibility: Skip TopNav Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors August 09, 2013 01:00 ET Cash runway extended to end of 2014 Geneva, Switzerland, 9 August 2013 - Addex Therapeutics (SIX: ADXN) announced today
Read more →ADXNAddex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down
Accessibility: Skip TopNav Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down May 31, 2013 12:03 ET Geneva, Switzerland, 31 May 2013 - Addex Therapeutics (SIX: ADXN) announced today that it has completed the restruc
Read more →ADXNAddex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders
Accessibility: Skip TopNav Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders May 28, 2013 01:00 ET Company intends to restructure the organization and monetize its pipeline and platform assets Geneva, Switzerland, 2
Read more →ADXNAddex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441
Accessibility: Skip TopNav Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441 May 21, 2013 01:30 ET · ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinica
Read more →ADXNAddex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study
Accessibility: Skip TopNav Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study May 01, 2013 01:00 ET · Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human
Read more →ADXNAddex Announces CFO, Tim Dyer, to Transition to External Consulting Role
Accessibility: Skip TopNav Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role April 30, 2013 14:44 ET Geneva, Switzerland, 30 April 2013 - Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and developme
Read more →ADXNAddex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence
Accessibility: Skip TopNav Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence April 30, 2013 01:00 ET Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator Recent approval
Read more →ADXNAddex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441
Accessibility: Skip TopNav Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441 April 24, 2013 01:00 ET ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half
Read more →ADXNAddex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant
Accessibility: Skip TopNav Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant April 22, 2013 01:47 ET Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare d
Read more →ADXNAddex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)
Accessibility: Skip TopNav Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) April 18, 2013 01:02 ET Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studie
Read more →ADXNAddex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)
Accessibility: Skip TopNav Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN) March 21, 2013 12:30 ET $1 MM grant by The Michael J. Fox Foundation to be used to help fund furthe
Read more →ADXNAddex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research
Accessibility: Skip TopNav Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research March 19, 2013 02:00 ET Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-
Read more →ADXNAddex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor
Accessibility: Skip TopNav Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor March 04, 2013 01:00 ET Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs
Read more →ADXNAddex Therapeutics Reports 2012 Financial Results
Accessibility: Skip TopNav Addex Therapeutics Reports 2012 Financial Results February 28, 2013 01:31 ET 2012 Financial Highlights CHF20.8 million of cash used, in line with the guidance of CHF20-21 million Cash and cash equivalents of CHF15.3 million at 31 December 2012 Cas
Read more →ADXNAddex to Focus Resources on Clinical Pipeline
Accessibility: Skip TopNav Addex to Focus Resources on Clinical Pipeline February 07, 2013 01:30 ET · Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication · Submit Orphan Drug Application in U.S. and Europe for dipragluran
Read more →ADXNAddex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia
Accessibility: Skip TopNav Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia January 29, 2013 01:00 ET Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase
Read more →ADXNAddex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441
Accessibility: Skip TopNav Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441 January 22, 2013 01:00 ET ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half
Read more →ADXNAddex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease
Accessibility: Skip TopNav Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease January 07, 2013 01:00 ET ADX71441, a novel oral small molecule positive allosteric modulator, on track for Phase 1 clinical testing in t
Read more →ADXNAddex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor
Accessibility: Skip TopNav Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor December 20, 2012 01:30 ET This is a significant breakthrough in the validation of this GPCR target for th
Read more →ADXNAddex' Dipraglurant Named as one of the "Top 10 Neuroscience Projects to Watch" by Windhover and Virginia Herndon
Accessibility: Skip TopNav Addex' Dipraglurant Named as one of the "Top 10 Neuroscience Projects to Watch" by Windhover and Virginia Herndon November 27, 2012 01:00 ET Geneva, Switzerland, 27 November 2012 - (SIX:ADXN), a leading company pioneering allosteric modulation-based
Read more →ADXNAddex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients
Accessibility: Skip TopNav Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients November 05, 2012 01:00 ET Key objectives achieved Safety and tolerability demonstrated Sub population identified for potential treatment
Read more →ADXNAddex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking
Accessibility: Skip TopNav Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking October 29, 2012 02:00 ET Data reinforces broad therapeutic potential of oral ADX71441 Program on track for CTA filing before end of 2012 Geneva, Switzer
Read more →ADXNAddex Updates Financial Guidance for 2012
Accessibility: Skip TopNav Addex Updates Financial Guidance for 2012 October 24, 2012 01:00 ET 2012 full year cash utilization of CHF20-21 million Geneva, Switzerland, 24 October 2012 - (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and de
Read more →ADXNAddex Therapeutics raises $10 million in a Private Placement to International Institutional Investors
Accessibility: Skip TopNav Addex Therapeutics raises $10 million in a Private Placement to International Institutional Investors October 12, 2012 12:00 ET Geneva, Switzerland, 12 October 2012 - Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-b
Read more →ADXNAddex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting
Accessibility: Skip TopNav Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting October 11, 2012 01:50 ET Research highlights include data from Addex' programs in Alzheimer's, Parkinson's, psychiatry indi
Read more →ADXNAddex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
Accessibility: Skip TopNav Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases October 02, 2012 01:05 ET Grant to Further Characterize Allosteric Modulators Against mGluR4 and mGluR7 Geneva, Switzerla
Read more →ADXNAddex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model - A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
Accessibility: Skip TopNav Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model - A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis September 24, 2012 01:00 ET Geneva, Switzerland, 24 September 2012 - Addex Therapeutics (SIX:ADXN),
Read more →ADXNAddex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms
Accessibility: Skip TopNav Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms September 17, 2012 01:00 ET Geneva, Switzerland, 17 September 2012 - Addex Therapeutics (SIX:ADXN),
Read more →ADXNAddex Therapeutics First Half 2012 Financial Results
Accessibility: Skip TopNav Addex Therapeutics First Half 2012 Financial Results August 22, 2012 01:00 ET Geneva, Switzerland, 22 August 2012 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced tod
Read more →ADXNAddex Therapeutics First Half 2012 Financial Results Next Wednesday
Accessibility: Skip TopNav Addex Therapeutics First Half 2012 Financial Results Next Wednesday August 20, 2012 01:28 ET Geneva, Switzerland, 20 August 2012 - Addex Therapeutics (SIX:ADXN), a leading biopharmaceutical company pioneering allosteric modulation-based drug discover
Read more →ADXNAddex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models
Accessibility: Skip TopNav Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models July 16, 2012 01:00 ET Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Mod
Read more →ADXNAddex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research
Accessibility: Skip TopNav Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research July 03, 2012 01:00 ET Geneva, Switzerland, 3 July 2012 - Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based oral small molecule dru
Read more →ADXNAddex to Present Phase 2a Dipraglurant Data at Movement Disorder Society's International Congress
Accessibility: Skip TopNav Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society's International Congress June 18, 2012 12:00 ET Geneva, Switzerland, 18 June 2012 - Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug
Read more →ADXNAddex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms
Accessibility: Skip TopNav Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms June 05, 2012 01:00 ET Geneva, Switzerland, 5 June 2012 - Addex Therapeutics Ltd (SIX:ADXN), a leading company pioneerin
Read more →ADXNAddex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder
Accessibility: Skip TopNav Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder April 16, 2012 01:00 ET Program on track for IND filing before end of 2012 GABA-BR PAM compounds have potential in several major Indications Geneva, S
Read more →ADXNAddex Takes Steps to Rightsize Operations and Position the Company for Future Success
Accessibility: Skip TopNav Addex Takes Steps to Rightsize Operations and Position the Company for Future Success April 13, 2012 12:00 ET Geneva, Switzerland, April 13, 2012 - Addex Therapeutics (SIX:ADXN), a leading organization pioneering allosteric modulation-based oral smal
Read more →ADXNAddex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
Accessibility: Skip TopNav Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) March 21, 2012 13:00 ET All key objectives achieved Safety and tolerability demonstrated Statistically significant reduction
Read more →ADXNAddex Changes Name to Addex Therapeutics, Launches New Website and Corporate Branding
Accessibility: Skip TopNav Addex Changes Name to Addex Therapeutics, Launches New Website and Corporate Branding March 21, 2012 02:30 ET Geneva, Switzerland, 21 March 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discove
Read more →ADXNAddex Pharmaceuticals Reports 2011 Financial Results
Accessibility: Skip TopNav Addex Pharmaceuticals Reports 2011 Financial Results February 23, 2012 01:00 ET Financial Highlights Cash and cash equivalents of CHF36.1 million at 31 December 2011 Cash can fund operations through to 3Q 2013 Restructuring and pipeline prioritiza
Read more →ADXNAddex Pharmaceuticals 2011 Financial Results This Thursday
Accessibility: Skip TopNav Addex Pharmaceuticals 2011 Financial Results This Thursday February 21, 2012 12:00 ET Geneva, Switzerland, 21 February 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading biopharmaceutical company pioneering allosteric modulation-based drug discovery
Read more →ADXNAddex to Present at the BIO CEO & Investor Conference
Accessibility: Skip TopNav Addex to Present at the BIO CEO & Investor Conference February 10, 2012 01:00 ET Geneva, Switzerland, February 10, 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading biopharmaceutical company pioneering allosteric modulation-based drug discovery and
Read more →ADXNAddex: Better Tolerated Formulation of ADX10059 Reduces Acid Reflux
Second trial showing mGluR5 inhibition reduces reflux in humans Side effects dramatically reduced by formulation Twice-daily oral dosing achieved Doses selected for Phase IIb trials Phase IIb GERD and migraine trials to start in 4Q08 Geneva, Switzerland, 10 September 2008 -
Read more →ADXNAddex Pharmaceuticals Reports First Half 2008 Financial Results, Maiden Profit
Français (PDF) Deutsch (PDF) English (PDF) Geneva, Switzerland, 28 July 2008 - Addex Pharmaceuticals (SWX:ADXN) released today financial results for the first half of 2008 and gave an update on the status of its lead product, ADX10059, which is in development for GERD (gastroe
Read more →ADXNAddex Appoints Laurent Galibert Head of Inflammation Business Unit
Geneva, Switzerland, 28 July 2008 - Addex Pharmaceuticals is pleased to announce the appointment of Laurent Galibert to its executive management team, as head of the Addex Inflammation Business Unit. Vincent Mutel, CEO, said, "I am confident that Dr. Galibert's expertise and lea
Read more →ADXNAddex First Half 2008 Financial Results Monday, July 28
Geneva, Switzerland, 18 July 2008 - Addex Pharmaceuticals Ltd. (SWX:ADXN) will discuss its financial results for the first half of 2008 and give a pipeline update during a teleconference and webcast for investors, analysts and the media on Monday, July 28 at 16:00 CET. Title: Ad
Read more →ADXNAddex Pharmaceuticals Starts Phase I ADX10059 Interaction Study
New formulation of ADX10059 selected Geneva, Switzerland, 4 June 2008 - Addex Pharmaceuticals (SWX:ADXN) announced that it has started Study 105, a Phase I clinical trial evaluating the interaction of a new formulation of ADX10059 with proton pump inhibitors and food. A formulat
Read more →ADXNAddex Starts ADX10059 Phase I Formulation Selection Study
Geneva, Switzerland, 24 April 2008 - Addex Pharmaceuticals (SWX:ADXN) announced that it has begun Phase I testing of two formulations of ADX10059 and that it will elaborate on ADX10059 development and its pipeline during today's R&D day. Charlotte Keywood, chief medical officer,
Read more →ADXNAddex Shareholders Elect Ray Hill to Board of Directors at the 2008 Annual General Meeting
Shareholders Approve All Board Proposals at 2008 AGM Geneva, Switzerland, 18 April 2008 - Addex Pharmaceuticals Ltd. (SWX:ADXN) announced that its shareholders approved all the proposals of the board of directors at its 2008 annual general meeting ("2008 AGM") today. In particul
Read more →ADXNAddex Appoints Laurent Massuyeau as Head of Business Development
Geneva, Switzerland, 18 April 2008 - Addex Pharmaceuticals is pleased to announce the appointment of Laurent Massuyeau as head of business development. Mr. Massuyeau joins Addex from Idenix Pharmaceuticals Inc., where he was executive director of European commercial operations.
Read more →ADXNAddex Pharmaceuticals R&D Day on April 24
Addex 2007 Annual Report Now Available Geneva, Switzerland, 28 March 2008 - Addex Pharmaceuticals (SWX:ADXN) invites investors, analysts and media to attend its first R&D day on Thursday, April 24, 2008 in Geneva, Switzerland. We will discuss the status and development plans fo
Read more →ADXNAddex Pharmaceuticals 2007 Financial Results
Addex 2007 Financial Results (PDF) Addex 2007 résultats financiers (PDF) Addex Finanzergebnis 2007 (PDF) Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) released today 2007 financial results and reiterated the status of its pipeline. Finan
Read more →ADXNAddex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collabo
Read more →ADXNaddex full year 2007 financial results next tuesday
addex full year 2007 financial results next tuesday
Read more →ADXNAddex Announces ADX10059 Phase IIa Acute Anxiety Data
Teleconference & Webcast Today at 17:00 CET (11 am EDT) Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. Howev
Read more →ADXNAddex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia
Second Merck Deal Demonstrates the Value of Addex' Allosteric Modulator Platform Addex to Host Webcast and Conference Call Today at 5:00 pm CET (11:00 am EST) Geneva, Switzerland, 3 January 2008 - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced today th
Read more →ADXNAddex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease Addex to Host Webcast and Conference Call Today at 5:00 pm CET (11:00 am EST) Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced today that it has enter
Read more →ADXNAddex Webcast and Conference Call on Monday
Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) will hold a conference call on Monday, 3 December 2007 at 5:00 pm CET (11:00 am EST). A press release will be issued at 7:00 am CET (1:00 am EST) on Monday disclosing the subject of the call. We
Read more →ADXNAddex Pharmaceuticals Confirms Extension of Major Shareholder Lock-up
Disclosure of Change in Shareholder Group as per Article 15 of the Ordinance of the Federal Banking Commission on the Stock Exchange of June 25, 1997 Geneva, Switzerland - Allosteric modulation company Addex Pharmaceuticals Ltd (SWX:ADXN) today confirmed that its major pre-IPO s
Read more →ADXNAddex Presents ADX10059 GERD Data at Conference
English Version in PDF Format French Version in PDF Format German Version in PDF Format - Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN, Geneva, Switzerland) presented new data from its Phase IIa trial of ADX10059 to treat gastroesophageal reflux disease (GERD)
Read more →ADXNAddex Pharmaceuticals appoints Head of ADME/PK
Geneva, Switzerland, 17 August 2007 - Allosteric modulation company Addex Pharmaceuticals Ltd announced today that Bruno Bournique has been appointed Head of Absorption, Distribution, Metabolism and Excretion (ADME) / Pharmacokinetics (PK). Before joining Addex Dr. Bournique was
Read more →ADXNAddex Pharmaceuticals First Half 2007 Financial Results
Addex raised CHF137 million in IPO ADX10059 shows efficacy in GERD & Migraine Conference call & webcast at 15:30 CEST (9:30am EDT) English Release (PDF) German Release (PDF)
Read more →ADXNAddex First Half 2007 Financial Results Next Wednesday
Conference call & webcast at 15:30 CEST on 25 July 2007 Geneva, Switzerland, 18 July 2007 - Addex Pharmaceuticals Ltd. (SWX:ADXN) will discuss its first half 2007 financial results during a conference call for the media, analysts, investors and other interested parties on Wednes
Read more →ADXNAddex Pharmaceuticals Attracts Venture Funding From Leading European VC Firms
GENEVA, Switzerland, July 11, 2002 (PRIMEZONE) -- Addex Pharmaceuticals today announced the closing of a CHF 15.75 million first round ($10 million) coled by Index Ventures and Sofinnova Partners. Other investors include TVM (Techno Venture Management), BCV Initiative Capital and
Read more →Competitive Position
How ADXN ranks across every disease it competes inCompetitive Position is a premium feature
See how ADXN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial